Dr. Elias Zerhouni, Vice Chairman and President, said the post-transaction remaining BioReference operations represented approximately $300 million in revenue in 2025. He said testing volume in the fourth quarter, excluding the divested oncology assets, grew slightly, and that BioReference reduced its workforce by roughly 29% from the prior year to about 1,400 full-time employees as part of broader operational efficiency initiatives. Management said these changes significantly improved margins and underpin ...